Melissa A. King

ORCID: 0009-0005-0903-8886
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Mitochondrial Function and Pathology
  • Genetic Neurodegenerative Diseases
  • Cardiac Valve Diseases and Treatments
  • Aortic Disease and Treatment Approaches
  • ATP Synthase and ATPases Research
  • Aortic aneurysm repair treatments
  • DNA Repair Mechanisms
  • Yersinia bacterium, plague, ectoparasites research
  • Advanced MRI Techniques and Applications
  • Cardiac Structural Anomalies and Repair
  • Heparin-Induced Thrombocytopenia and Thrombosis
  • Infective Endocarditis Diagnosis and Management
  • Liver physiology and pathology
  • Cardiac and Coronary Surgery Techniques
  • Plant-based Medicinal Research
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Heart Failure Treatment and Management
  • Endoplasmic Reticulum Stress and Disease
  • Metabolism and Genetic Disorders
  • Venous Thromboembolism Diagnosis and Management
  • Cardiovascular Function and Risk Factors

University of Calgary
2019-2025

Libin Cardiovascular Institute of Alberta
2022-2024

University of British Columbia
2024

The dilated cardiomyopathy with ataxia (DCMA) syndrome is a rare mitochondrial disorder caused by mutations in the poorly understood DNAJC19 gene. Cardiac involvement DCMA ranges from mild conduction abnormalities to early severe myocardial dysfunction. Although evidence suggests that linked function, molecular underpinnings of this condition are unclear, and there no way predict which patients will develop life-threatening disease. To address this, we developed metabolic flux assay for...

10.1002/jimd.70018 article EN cc-by-nc-nd Journal of Inherited Metabolic Disease 2025-03-01

We used patient dermal fibroblasts to characterize the mitochondrial abnormalities associated with dilated cardiomyopathy ataxia syndrome (DCMA) and study effect of mitochondrially-targeted peptide SS-31 as a potential novel therapeutic. DCMA is rare understudied autosomal recessive disorder thought be related Barth but caused by mutations in DNAJC19, protein unknown function localized mitochondria. The clinical disease characterized 3-methylglutaconic aciduria, cardiomyopathy, abnormal...

10.3389/fcvm.2019.00167 article EN cc-by Frontiers in Cardiovascular Medicine 2019-11-15

IntroductionCarotid endarterectomy reduces the risk of recurrent stroke in symptomatic carotid stenosis. In patients with a history heparin-induced thrombocytopenia, heparin is contraindicated, and these require an alternative parenteral anticoagulant during endarterectomy. The aim this review was to literature for evidence use direct thrombin inhibitors (DTIs) (hirudin, hirudin derivates (lepirudin, desirudin, bivalirudin), argatroban) endarterectomy.MethodsA search conducted using MEDLINE...

10.1016/j.jvsvi.2024.100102 article EN cc-by JVS-Vascular Insights 2024-01-01

ABSTRACT Objectives We used patient dermal fibroblasts to characterize the mitochondrial abnormalities associated with dilated cardiomyopathy ataxia syndrome (DCMA) and study effect of mitochondrially-targeted peptide SS-31 as a potential novel therapeutic. Background DCMA is an understudied autosomal recessive disorder thought be related Barth but caused by mutations in DNAJC19 , protein unknown function localized mitochondria. The clinical disease characterized 3-methylglutaconic aciduria,...

10.1101/672857 preprint EN cc-by-nc-nd bioRxiv (Cold Spring Harbor Laboratory) 2019-06-17

Abstract Dilated cardiomyopathy with ataxia (DCMA) syndrome is a rare mitochondrial disorder caused by mutations in the poorly understood DNAJC19 gene. The clinical presentation of DCMA very diverse symptoms ranging from mild cardiac dysfunction to intractable heart failure leading death early childhood. Although several lines evidence indicate that are linked function, molecular underpinnings this disease unclear and there no way predict which patients at risk for developing...

10.1101/2020.10.11.334938 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2020-10-11
Coming Soon ...